Johnson & Johnson picks Golin to handle North America Skin Health PR

The IPG agency will build strategic earned media, social media and influencer plans for J&J’s Neutrogena, Clean & Clear and Aveeno brands in the U.S.

Golin will work on Neutrogena and other skin-care brands in the U.S. and Canada. (Image via Neutrogena's Facebook account)
Golin will work on Neutrogena and other skin-care brands in the U.S. and Canada. (Image via Neutrogena's Facebook account)

NEW BRUNSWICK, NJ: Johnson & Johnson’s Consumer Health division has selected Golin to handle PR for its North America Skin Health business, effective next year.

The company hired Golin for the seven-figure account after a review that took place over the summer.  

The Interpublic Group agency will build strategic earned media, social media and influencer relations plans for J&J’s Neutrogena, Clean & Clear and Aveeno brands in the U.S. and Neutrogena, Aveeno and J&J brands in Canada, according to a statement from the company.

“We believe Golin offers the right capabilities to support the growth objectives for our Skin Health business where we are focused on skin care products and solutions that are rooted in science and endorsed by healthcare professionals,” the company said in a statement. 

J&J works with dozens of PR agencies. Last year, Michael Sneed, EVP of global corporate affairs and chief communications officer, called WPP’s BCW "an important agency for us" and Omnicom’s Porter Novelli, Marina Maher and Ketchum "critical partners for our brands and companies." 

In March 2018, J&J asked WPP and Omnicom to take talent from their agencies and create integrated teams dedicated to serving J&J’s consumer efforts. WPP called its group Neighborhood and Omnicom’s was christened Velocity. Neighborhood drew staffers from BCW and Ogilvy, among other shops, while Velocity drafted talent from FleishmanHillard and Marina Maher Communications, Sneed said.

Representatives from Golin, BCW, FleishmanHillard, Porter Novelli, Rpr, Marina Maher and Ketchum were not immediately available for comment. 

J&J reported a sales decrease of 10.8% to $18.3 billion in Q2 as the company was affected by the COVID-19 pandemic. J&J said in its Q2 earnings statement that worldwide operational sales in its Consumer Health division dropped by 3.4%, with Skin Health and Beauty Care most affected by the pandemic.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in